David Hallal, Getty Images

David Hal­lal bags an­oth­er whop­per round, look­ing to re­cruit more cell and gene ther­a­py up­starts to El­e­vate­Bio Base­Camp

Less than a year af­ter at­tract­ing a launch round of $150 mil­lion, ex-Alex­ion chief David Hal­lal isn’t break­ing stride — yet — for a pan­dem­ic. His start­up cell and gene ther­a­py play­er El­e­vate­Bio in Waltham, MA has at­tract­ed an­oth­er whop­per round, with am­bi­tious plans to build up its port­fo­lio of up­starts.

The lat­est round in­cludes a bevy of new in­vestors: The In­vus Group, Sur­vey­or Cap­i­tal, ED­BI, and Ver­tex Ven­tures — backed by Temasek. They’re sign­ing up along­side ex­ist­ing in­vestors, in­clud­ing F2 Ven­tures, MPM Cap­i­tal, EcoR1 Cap­i­tal, Red­mile Group, and Sam­sara Bio­Cap­i­tal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.